Ground breaking molecular diagnostics business appoints new CEO
3rd February 2010
Renishaw Diagnostics (previously D3 Technologies Ltd), a world leading provider of trace level detection technologies based on the exploitation of Surface-Enhanced Raman Scattering (SERS) and Surface-Enhanced Resonance Raman Scattering (SERRS), today announced that it has appointed David Burns as its new Chief Executive Officer. He will lead the Company towards the international launch of its first in vitro diagnostic (IVD) products, with the aim to establish Renishaw Diagnostics as a global player in the field of molecular diagnostics for human infectious diseases. David has over 20 years of commercial life sciences experience, most recently as VP of Sales & Marketing with Cyntellect Inc, and before that as Head of Strategic Growth with GE Healthcare Life Sciences.
The Company's current CEO, Professor Ewen Smith, is standing down to focus on the technical development of the exciting portfolio of diagnostics products that Renishaw Diagnostics has targeted for the next few years. Speaking about the new appointment he said, “I am delighted to welcome David to the Company. We already have a strong multi-disciplinary technical team and with his proven leadership skills, international experience of the clinical molecular diagnostics market and excellent track record in business development, the future is very bright for Renishaw Diagnostics.”
David has gained extensive knowledge of sales, marketing and business development within the life sciences sector. Prior to GE Healthcare he also held senior roles within Amersham Biosciences, was CEO at Imaging Research Inc before its acquisition by Amersham, and VP of Business Development at BioSignal Packard Inc. “I am very excited by this new challenge,” said Mr Burns. “Renishaw Diagnostics has a tremendous future and I am looking forward to helping the team deliver world-class DNA-based diagnostic tests to detect diseases, or the genetic predisposition to diseases.” Ends
Enquiries: Caterina Netti, Head of Operations and Technology (+44 141 5577900)
About Renishaw Diagnostics Ltd
Renishaw Diagnostics Ltd, formerly D3 Technologies Ltd, was a Strathclyde University spin-out before being acquired by the Renishaw Group, which is a leading global supplier of engineering technologies, medical devices and Raman spectroscopy systems. It is focused on developing and commercialising its first in vitro diagnostic (IVD) and clinical research products, with the goal of establishing Renishaw Diagnostics as the premium provider of automated, multiplex, high sensitivity molecular diagnostics products for the detection of human infectious diseases.